These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23503714)

  • 1. Intermittent levosimendan treatment in patients with severe congestive heart failure.
    Tuomainen PO; Magga J; Timonen P; Miettinen K; Kurttila M; Vanninen E; Laitinen T; Timonen K; Punnonen K; Parviainen I; Uusaro A; Vuolteenaho O; Kivikko M; Peuhkurinen K
    Clin Res Cardiol; 2013 Jul; 102(7):485-93. PubMed ID: 23503714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we believe in levosimendan?
    Follath F
    Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
    Parissis JT; Adamopoulos S; Farmakis D; Filippatos G; Paraskevaidis I; Panou F; Iliodromitis E; Kremastinos DT
    Heart; 2006 Dec; 92(12):1768-72. PubMed ID: 17105880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension].
    Martyniuk TV; Arkhipova OA; Kobal' EA; Danilov NM; Chazova IE
    Ter Arkh; 2012; 84(9):83-8. PubMed ID: 23091860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure.
    Mavrogeni S; Giamouzis G; Papadopoulou E; Thomopoulou S; Dritsas A; Athanasopoulos G; Adreanides E; Vassiliadis I; Spargias K; Panagiotakos D; Cokkinos DV
    J Card Fail; 2007 Sep; 13(7):556-9. PubMed ID: 17826646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients.
    Parissis JT; Papadopoulos C; Nikolaou M; Bistola V; Farmakis D; Paraskevaidis I; Filippatos G; Kremastinos D
    Cardiovasc Drugs Ther; 2007 Aug; 21(4):263-8. PubMed ID: 17610056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
    Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
    Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
    Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
    Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure.
    Tasal A; Demir M; Kanadasi M; Bacaksiz A; Vatankulu MA; Sahin DY; Eker RA; Bozkurt A; Acarturk E
    Med Sci Monit; 2014 Feb; 20():276-82. PubMed ID: 24549281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with advanced heart failure and the effects of levosimendan.
    Song ZZ; Ma J
    Am J Cardiol; 2007 Aug; 100(4):742; author reply 742-3. PubMed ID: 17697841
    [No Abstract]   [Full Text] [Related]  

  • 11. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
    Zemljic G; Bunc M; Yazdanbakhsh AP; Vrtovec B
    J Card Fail; 2007 Aug; 13(6):417-21. PubMed ID: 17675054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
    Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
    Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of quality of life using three activity questionnaires in heart failure patients after monthly, intermittent administration of levosimendan during a six-month period.
    Papadopoulou EF; Mavrogeni SI; Dritsas A; Cokkinos DV
    Hellenic J Cardiol; 2009; 50(4):269-74. PubMed ID: 19622496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.
    Büyüklü M; Kürüm AT; Tatlý E; Set T
    Arq Bras Cardiol; 2012 Jul; 99(1):659-64. PubMed ID: 22735864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
    Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
    Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.